Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Next Previous
X
Search
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Ascending Dose Cohort Study to Evaluate Safety and Efficacy of a Single Treatment Cycle of EB-001 in Subjects With Glabellar Frown Lines

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 20 Feb 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Botulinum toxin E (Primary)
  • Indications Glabellar lines
  • Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
  • Sponsors Bonti

    • Most Recent Events

    • 09 Oct 2017 According to a Bonti media release, results were presented at Plastic Surgery The Meeting 2017 organized by the American Society of Plastic Surgeons (ASPS).
    • 13 Sep 2017 According to a Bonti media release, results from this study will be presented at the American Society for Dermatological Surgery (ASDS) Annual Meeting 2017.
    • 16 Aug 2017 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top